The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
2-(1-amino-2-(1H-imidazol-5-yl)ethyl)-6-phenylquinazolin-4(3H)-one ID: ALA5193472
PubChem CID: 168284637
Max Phase: Preclinical
Molecular Formula: C19H17N5O
Molecular Weight: 331.38
Associated Items:
Names and Identifiers Canonical SMILES: NC(Cc1cnc[nH]1)c1nc2ccc(-c3ccccc3)cc2c(=O)[nH]1
Standard InChI: InChI=1S/C19H17N5O/c20-16(9-14-10-21-11-22-14)18-23-17-7-6-13(8-15(17)19(25)24-18)12-4-2-1-3-5-12/h1-8,10-11,16H,9,20H2,(H,21,22)(H,23,24,25)
Standard InChI Key: MSQRWTZUUURCRC-UHFFFAOYSA-N
Molfile:
RDKit 2D
25 28 0 0 0 0 0 0 0 0999 V2000
-1.7244 0.9087 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0098 1.3210 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.2979 0.9091 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.2979 0.0839 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0080 -0.3278 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.7244 0.0802 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.4391 1.3212 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.1539 0.9089 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.8659 1.3209 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.8659 2.1463 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.1556 2.5582 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.4391 2.1500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.4166 1.3217 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.1313 0.9090 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.1313 0.0839 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.4166 -0.3286 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.4166 2.1468 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1.8459 -0.3286 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5605 0.0839 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.8459 -1.1538 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5605 -1.5664 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.3140 -1.2309 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.8659 -1.8439 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.4536 -2.5582 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.6468 -2.3867 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 1 0
4 3 2 0
5 4 1 0
1 6 1 0
6 5 2 0
7 1 1 0
8 7 2 0
9 8 1 0
10 9 2 0
11 10 1 0
7 12 1 0
12 11 2 0
3 13 1 0
14 13 1 0
15 14 1 0
16 15 2 0
4 16 1 0
13 17 2 0
15 18 1 0
18 19 1 0
18 20 1 0
20 21 1 0
22 21 1 0
22 23 1 0
23 24 2 0
24 25 1 0
25 21 2 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 331.38Molecular Weight (Monoisotopic): 331.1433AlogP: 2.56#Rotatable Bonds: 4Polar Surface Area: 100.45Molecular Species: NEUTRALHBA: 4HBD: 3#RO5 Violations: ┄HBA (Lipinski): 6HBD (Lipinski): 4#RO5 Violations (Lipinski): ┄CX Acidic pKa: 9.66CX Basic pKa: 8.02CX LogP: 1.14CX LogD: 0.48Aromatic Rings: 4Heavy Atoms: 25QED Weighted: 0.53Np Likeness Score: -0.79
References 1. Burley R, Hewer RC, Teall M, Dickson L, Ossola B, Russell S, Bender C, Cheung T, Powell JAC, Xu X, Brice NL, Otter L, Arimont M, Kidd SL, Vidal D, Dale JW, Mervin L, Sore HF, Mateu N, Lakshminarayana N, Dawson LA, Carlton M, Bürli RW.. (2022) Synthesis and SAR of novel GPR39 agonists and positive allosteric modulators., 61 [PMID:35123006 ] [10.1016/j.bmcl.2022.128607 ]